Company intelligence / Profile preview
Zhejiang Teruisi Pharmaceutical Inc.
Huzhou, Zhejiang, Chinateruisipharm.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
The company has multiple products in development, with its recombinant humanized anti-VEGF monoclonal antibody in Phase 3. TRS-005 received breakthrough therapy designation from China's NMPA in March 2024 for relapsed/refractory CD20-positive diffuse large B-cell lymphoma.
- Therapeutic areas
- OncologyDermatology
- Modalities
- Monoclonal antibodiesAntibody-drug conjugatesBiosimilarsBiological products
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
Beyond the preview
Go deeper on Zhejiang Teruisi Pharmaceutical Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Zhejiang Teruisi Pharmaceutical Inc..